Prelude Therapeutics Incorporated Company Profile
NASDAQ: PRLDHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Prelude Therapeutics at a glance
Prelude Therapeutics Incorporated (NASDAQ: PRLD) is a Biotechnology company in the Healthcare sector headquartered in Wilmington, DE. Prelude Therapeutics is led by Dr. Krishna Vaddi D.V.M., Ph.D. and employs about 79 people. The company's shares have traded publicly since 2020.
At a market capitalization of $304.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001678660, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Prelude Therapeutics do?
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Business description based on the company's public filings.
Company information
- Legal name
- Prelude Therapeutics Incorporated
- Ticker
- NASDAQ: PRLD
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Krishna Vaddi D.V.M., Ph.D.
- Employees
- 79
- Headquarters
- 175 Innovation Boulevard, Wilmington, DE, United States
- Phone
- 302 467 1280
- Website
- preludetx.com
- IPO year
- 2020
- Market cap
- $304.05M
- SEC CIK
- 0001678660
Companies similar to Prelude Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INDPIndaptus Therapeutics Inc. | 2.26 | -12.74% | $301.13M | vs PRLD |
| SRZNSurrozen Inc. | 25.15 | -4.65% | $295.54M | vs PRLD |
| BNTCBenitec Biopharma Inc. | 8.99 | -0.11% | $313.60M | vs PRLD |
| CUVLClinuvel Pharmaceuticals Limited ADR | 5.80 | +2.29% | $292.83M | vs PRLD |
| ABEOAbeona Therapeutics Inc. | 5.08 | +1.40% | $290.49M | vs PRLD |
| LRMRLarimar Therapeutics Inc. | 2.75 | -1.08% | $285.68M | vs PRLD |
| FULCFulcrum Therapeutics Inc. | 3.67 | -0.54% | $280.01M | vs PRLD |
| XFORX4 Pharmaceuticals Inc. | 2.81 | +1.44% | $278.60M | vs PRLD |